|Bid||37.87 x 800|
|Ask||60.00 x 800|
|Day's Range||37.50 - 38.54|
|52 Week Range||28.54 - 46.43|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||18.64|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.50|
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Affimed (AFMD) exceeds earnings and sales estimates in the first quarter of 2019. The company also plans to focus its research and development investments.
Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced plans to showcase its regenerative medicine and orthobiologics portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine Congress being held in Cancun, Mexico ...
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you're interested in Anika Therapeutics, Inc. (NASDAQ:ANIK), then you might want to consider its b...
Anika (ANIK) delivered earnings and revenue surprises of 47.62% and 14.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Bedford, Massachusetts-based company said it had net income of 31 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that its Board of Directors has authorized the repurchase of up to $50 million of the Company’s shares of common stock. Anika plans to purchase $30 million of shares under an accelerated share repurchase (ASR) program and $20 million of shares from time to time on the open market. “We are pleased to continue returning cash to shareholders through share repurchases, as we transform Anika into a global commercial company,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics.
Seasoned commercial leader to oversee hybrid commercial organization and upcoming launch of Bone Repair Surgical Therapy in the U.S. Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Stephen Goldy to the newly created position of Vice President of U.S. Sales. Mr. Goldy brings over 20 years of experience developing and implementing sales strategy, with a specialization in the orthopedic, sports medicine and general surgery markets.
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anika Therapeutics, Inc. today announced that the Company plans to issue its first-quarter 2019 financial results after the close of the market on Thursday, May 2, 2019 and hold its investor conference call on the same day, Thursday, May 2, 2019, at 5:00 p.m.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do b...